Active Filter(s):
Details:
VBI-2902 is a monovalent Covid-19-specific vaccine expressing the SARS-CoV-2 spike protein. The adaptive Phase 1/2 clinical study will evaluate the safety, tolerability, and immunogenicity of VBI-2902, adjuvanted with aluminum phosphate.
Lead Product(s): VBI-2902,Aluminum Phosphate
Therapeutic Area: Infections and Infectious Diseases Product Name: VBI-2902
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2021